Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

BTK

16 posts
RRoche
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Read More

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

  • 2026-07-06
Nurix Therapeutics, Inc. Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted…
RRoche
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Read More

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • 2026-06-13
F. Hoffmann-La Roche Ltd Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell…
RRoche
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Read More

Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg

  • 2026-06-12
Roche RHHBY has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics NRIX to co-develop and…
RRoche
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Read More

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • 2026-06-11
F. Hoffmann-La Roche Ltd Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell…
RRoche
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Read More

Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg

  • 2026-06-10
Roche RHHBY has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics NRIX to co-develop and…
RRoche
Roche and Nurix strike $2.3 billion blood cancer drug deal
Read More

Roche and Nurix strike $2.3 billion blood cancer drug deal

  • 2026-06-09
Roche entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, an…
RRoche
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Read More

Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg

  • 2026-06-08
Roche RHHBY has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics NRIX to co-develop and…
RRoche
Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg
Read More

Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg

  • 2026-06-08
Roche has entered into a major licensing and collaboration agreement with Nurix Therapeutics for bexobrutideg, an investigational Bruton’s…
RRoche
Roche headquarters Basel
Read More

Roche bets on BTK degradation in $2.3bn Nurix deal

  • 2026-06-08
Under the agreement, Nurix will receive US$700m upfront and could earn development, regulatory and sales milestones bringing the…
RRoche
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Read More

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • 2026-06-08
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche’s…
RRoche
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Read More

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • 2026-06-08
F. Hoffmann-La Roche Ltd Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell…
NNovartis
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
Read More

Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings

  • 2026-04-24
The European drug market could soon be poised to receive three new entries, as the European Committee for…
Switzerland
www.europesays.com